Myelodysplastic syndrome (MDS) is the commonest of hematological malignancy. However, hematologists find it difficult to diagnose it with accuracy as there is no single test which is diagnostic. Clinical picture, morphology, cytogenetics and molecular tests compliment each other. Clinical severity is variable with some having survival in decades while others succumb within 1-2 years. Next-generation sequencing (NGS) based molecular testing has boosted the diagnostic skills and also added to targeted therapies using novel agents.
In the field of acute myeloblastic leukaemia (AML), there was no break through in the treatment for almost 2 decades. During 2018-19, almost half a dozen molecules have received US FDA approval and hence greatly enhanced survival of these patients. Today's presentation will review these molecules.
This course is relevant for Clinical Hematologists, Hematopathologists, Medical Oncologists and Fellows doing superspecialization in these fields